No Data
Express News | CervoMed Inc - to Report Topline Data From Phase 2B Dlb Trial in December 2024
Express News | CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
CervoMed Inc. (NASDAQ:CRVO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
D. Boral Capital Initiates Coverage On CervoMed With Buy Rating, Announces Price Target of $34
CervoMed Is Maintained at Buy by Chardan Capital
CervoMed Price Target Maintained With a $55.00/Share by Chardan Capital
No Data
No Data
